Track the companies that matter to you. It's FREE! Click one of these fan favorites to get started: Apple; Google; Ford.



Could This 1 Lawsuit Destroy Biogen Idec Stock?

Source: Biogen IDEC.

Biogen's (NASDAQ: BIIB  ) Tecfidera launched a year ago, and it has already become a blockbuster likely to notch more than $2 billion in sales this year. Much of Tecfidera's success is coming at the expense of recently launched oral multiple sclerosis drugs from Novartis (NYSE: NVS  ) and Sanofi (NYSE: SNY  ) , which market Gilenya and Aubagio, respectively.

As Tecfidera rolls out globally, Novartis and Sanofi are likely to lose additional market share over the coming year, but neither company is sitting still. Both are among a slate of generic drug makers that have filed opposition to a key EU patent on Tecfidera that gives Tecfidera exclusivity until 2028. 

In the following slideshow, you'll learn more about the patent threat to Biogen's fast growing drug and what the impact on Biogen may be if the EU's patent office sides with Novartis and Sanofi.

Leaked: This coming blockbuster will make Biogen jealous
The best biotech investors consistently reap gigantic profits by recognizing true potential earlier and more accurately than anyone else. Let me cut right to the chase. There is a product in development that will revolutionize not just how we treat a common chronic illness, but potentially the entire health industry. Analysts are already licking their chops at the sales potential. In order to outsmart Wall Street and realize multi-bagger returns, you will need The Motley Fool's new free report on the dream team responsible for this game-changing blockbuster. CLICK HERE NOW.

Read/Post Comments (0) | Recommend This Article (1)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 3038866, ~/Articles/ArticleHandler.aspx, 8/31/2015 2:10:54 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Todd Campbell

Todd has been helping buy side portfolio managers as an independent researcher for over a decade. In 2003, Todd founded E.B. Capital Markets, LLC, a research firm providing action oriented ideas to professional investors. Todd has provided insight to a variety of publications, including SmartMoney, Barron's, and CNN/fn.

Today's Market

updated Moments ago Sponsored by:
DOW 16,551.24 -91.77 -0.55%
S&P 500 1,977.48 -11.39 -0.57%
NASD 4,800.03 -28.29 -0.59%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

8/31/2015 1:55 PM
BIIB $301.12 Down -2.58 -0.85%
Biogen Idec CAPS Rating: ****
NVS $97.60 Down -0.75 -0.76%
Novartis CAPS Rating: ****
SNY $49.27 Down -0.01 -0.02%
Sanofi (ADR) CAPS Rating: *****